RAPT Therapeutics, Inc. (RAPT) Tops Q2 EPS by 1c

RAPT Therapeutics, Inc. (NASDAQ: RAPT) reported Q2 EPS of ($0.71), $0.01 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on RAPT Therapeutics, Inc. (RAPT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
• Rothschild Redburn Upgrades Apple (AAPL) to Buy